Previous Article | Next Article ![]()
Journal of Virology, March 2001, p. 2174-2184, Vol. 75, No. 5
Section of Molecular Genetics and
Microbiology and Institute for Cellular and Molecular Biology, The
University of Texas at Austin, Austin, Texas
78712,1 and Department of Biochemistry
and Molecular Biology, Feist-Weiller Cancer Center, Louisiana State
University Medical Center, Shreveport, Louisiana
711302
Received 10 October 2000/Accepted 6 December 2000
Type B leukemogenic virus (TBLV) induces rapidly appearing T-cell
tumors in mice. TBLV is highly related to mouse mammary tumor virus
(MMTV) except that TBLV long terminal repeats (LTRs) have a deletion of
negative regulatory elements and a triplication of sequences flanking
the deletion. To determine if the LTR triplication represents a viral
enhancer element, we inserted the triplication upstream and downstream
in either orientation relative to the thymidine kinase promoter linked
to the luciferase gene. These experiments showed that upregulation of
reporter gene activity by the TBLV triplication was relatively
orientation independent, consistent with the activity of eukaryotic
enhancer elements. TBLV enhancer activity was observed in T-cell lines
but not in fibroblasts, B cells, or mammary cells, suggesting that
enhancer function is cell type dependent. To analyze the transcription factor binding sites that are important for TBLV enhancer function, we
prepared substitution mutations in a reconstituted C3H MMTV LTR that
recapitulates the deletion observed in the TBLV LTR. Transient
transfections showed that a single mutation (556M) decreased TBLV
enhancer activity at least 20-fold in two different T-cell lines. This
mutation greatly diminished AML-1 (recently renamed RUNX1) binding in
gel shift assays with a mutant oligonucleotide, whereas AML-1 binding
to a wild-type TBLV oligomer was specific, as judged by competition and
supershift experiments. The 556 mutation also reduced TBLV enhancer
binding of two other protein complexes, called NF-A and NF-B, that did
not appear to be related to c-Myb or Ets. AML-1
overexpression in a mammary cell line enhanced expression from the TBLV
LTR approximately 30-fold. These data suggest that binding of AML-1 to
the TBLV enhancer, likely in combination with other factors, is
necessary for optimal enhancer function.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2174-2184.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Type B Leukemogenic Virus Has a T-Cell-Specific
Enhancer That Binds AML-1
*
Corresponding author. Mailing address: Section of
Molecular Genetics and Microbiology, The University of Texas at Austin, 100 W. 24th St., ESB 226, Austin, TX 78705. Phone: (512) 471-8415. Fax:
(512) 471-7088. E-mail: jdudley{at}uts.cc.utexas.edu.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|